NIH trial success suggests a new treatment option for older, sicker patients
Adults stop anti-rejection drugs after stem-cell transplant reverses sickle cell disease NIH trial success suggests a new treatment option for older, sicker patients
Half of patients in a trial have safely stopped immunosuppressant medication following a modified blood stem-cell transplant for severe sickle cell disease, according to a study in the July 1 issue of the Journal of the American Medical Association. The trial was conducted at the National Institutes of Health‘s Clinical Center in Bethesda, Maryland, by researchers from NIH’s National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the National Heart, Lung, and Blood Institute.
The transplant done in the study reversed sickle cell disease in nearly all the patients. Despite having both donor stem-cells and their own cells in their blood, the patients stopped the immunosuppressant medication without experiencing rejection or graft-versus-host disease, in which donor cells attack the recipient. Both are common, serious side effects of transplants.
“Typically, stem-cell recipients must take immunosuppressants all their lives,” said Matthew Hsieh, M.D., lead author on the paper and staff clinician at NIH. “That the patients who discontinued this medication were able to do so safely points to the stability of the partial transplant regimen.”
Read more . . .
The Latest on: Sickle cell disease
via Google News
The Latest on: Sickle cell disease
- CRISPR technology to cure sickle cell diseaseon January 21, 2021 at 9:36 am
University of Illinois Chicago is one of the U.S. sites participating in clinical trials to cure severe red blood congenital diseases such as sickle cell anemia or Thalassemia by safely modifying the ...
- “Cast aside and forgotten:” New report reveals that people with sickle cell have been neglected during pandemicon January 21, 2021 at 6:01 am
PEOPLE THAT suffer from sickle cell and thalassemia have been neglected during the coronavirus pandemic, a new report reveals. Published by The All-Party Parliamentary Group for Sickle Cell and ...
- Sickle cell sufferers negatively impacted by Covid says Harlesden charity chiefon January 20, 2021 at 9:54 am
Those with sickle cell disease are more likely to suffer from Covid-19 even if they do not catch it, according to a new report.
- Sickle Cell Disease Treatment Market Will Benefit from Rising Prevalence of Sickle Disease Around the World, says Fortune Business Insightson January 20, 2021 at 5:30 am
Increasing impetus to research on gene therapy to treat sickle cell disease is a key factor contributing to the ...
- CRISPR technology to cure sickle cell disease at UICon January 19, 2021 at 9:00 pm
The first cases treated with gene-editing technology were recently published in an article co-authored by Dr. Damiano Rondelli, the Michael Reese Professor of Hematology at the UIC College of Medicine ...
- Henderson family coping with sickle cell disease raises awareness of the disorderon January 19, 2021 at 2:13 am
Gia Glass explains her lifelong medical condition with the maturity of a child who is growing up in hospitals, yet with the simplicity of other 5-year-olds. Diagnosed through a routine blood screening ...
- People with sickle cell ‘cast aside and forgotten’ because of the pandemicon January 19, 2021 at 2:04 am
Sickle cell disease is an inherited blood condition which predominantly affects people from African and Caribbean backgrounds. People with this illness fall into the ‘extremely vulnerable’ group, so ...
- Aruvant Chooses Lonza to Manufacture ARU-1801, a Potentially Curative Treatment for Sickle Cell Disease, for Pivotal Trialon January 18, 2021 at 6:45 am
Aruvant Sciences, a private company focused on developing gene therapies for rare diseases, and Lonza announced today their agreement in support of ARU-1801, Aruvant’s one-time investigational gene ...
- Sickle cell disease and overcoming shame (I)on January 15, 2021 at 4:00 pm
I like it when people send me their stories to share with the readers as I feel it is important for people to know how sickle cell disease impacts on other areas of one’s life. Please read the story ...
- JPM: Imara CEO Ballal on fighting sickle cell disease during COVID-19on January 13, 2021 at 7:51 am
COVID-19 threw a wrench in Imara’s plans. The company was testing a treatment for sickle cell disease—which occurs more often in people of African descent—during a pandemic that disproportionately ...
via Bing News
